Prognostic value of early, conventional proton magnetic resonance spectroscopy in cooled asphyxiated infants by Barta, Hajnalka et al.
RESEARCH ARTICLE Open Access
Prognostic value of early, conventional
proton magnetic resonance spectroscopy
in cooled asphyxiated infants
Hajnalka Barta1* , Agnes Jermendy1, Marton Kolossvary2, Lajos R. Kozak3, Andrea Lakatos3, Unoke Meder1,
Miklos Szabo1† and Gabor Rudas3†
Abstract
Background: Neonatal hypoxic-ischemic encephalopathy (HIE) commonly leads to neurodevelopmental impairment,
raising the need for prognostic tools which may guide future therapies in time. Prognostic value of proton MR
spectroscopy (H-MRS) between 1 and 46 days of age has been extensively studied; however, the reproducibility
and generalizability of these methods are controversial in a general clinical setting. Therefore, we investigated the
prognostic performance of conventional H-MRS during first 96 postnatal hours in hypothermia-treated asphyxiated
neonates.
Methods: Fifty-one consecutive hypothermia-treated HIE neonates were examined by H-MRS at three echo-times
(TE = 35, 144, 288 ms) between 6 and 96 h of age, depending on clinical stability. Patients were divided into favorable
(n = 35) and unfavorable (n = 16) outcome groups based on psychomotor and mental developmental index (PDI and
MDI, Bayley Scales of Infant Development II) scores (≥ 70 versus < 70 or death, respectively), assessed at 18–26 months
of age. Associations between 36 routinely measured metabolite ratios and outcome were studied. Age-dependency of
metabolite ratios in whole patient population was assessed. Prognostic performance of metabolite ratios was evaluated
by Receiver Operating Characteristics (ROC) analysis.
Results: Three metabolite ratios showed significant difference between outcome groups after correction for multiple
testing (p < 0.0014): myo-inositol (mIns)/N-acetyl-aspartate (NAA) height, mIns/creatine (Cr) height, both at TE = 35 ms,
and NAA/Cr height at TE = 144 ms. Assessment of age-dependency showed that all 3 metabolite ratios (mIns/NAA,
NAA/Cr and mIns/Cr) stayed constant during first 96 postnatal hours, rendering them optimal for prediction. ROC
analysis revealed that mIns/NAA gives better prediction for outcome than NAA/Cr and mIns/Cr with cut-off values 0.
6798 0.6274 and 0.7798, respectively, (AUC 0.9084, 0.8396 and 0.8462, respectively, p < 0.00001); mIns/NAA had the
highest specificity (95.24%) and sensitivity (84.62%) for predicting outcome of neonates with HIE any time during the
first 96 postnatal hours.
Conclusions: Our findings suggest that during first 96 h of age even conventional H-MRS could be a useful prognostic
tool in predicting the outcome of asphyxiated neonates; mIns/NAA was found to be the best and age-independent
predictor.
Keywords: Perinatal asphyxia, Hypoxic-ischemic encephalopathy, Proton magnetic resonance spectroscopy, Conventional
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Background
Perinatal asphyxia and consequential hypoxic-ischemic
encephalopathy (HIE) remains one of the leading causes
of perinatal brain injury, affecting more than two million
neonates yearly worldwide [1]. Although full recovery is
possible, HIE can also lead to permanent mental or psy-
chomotor disability [2].
Currently, therapeutic hypothermia is the one and only
neuroprotective method proven effective to reduce mor-
tality and long-term morbidity in HIE [3]. However,
mortality or moderate to severe developmental delay still
affects over 40% of cooled infants, demanding future
therapeutic approaches additional to hypothermia [4, 5].
In theory, the key to successful neuroprotection is the
earliest possible initiation regardless of the therapy
chosen [6]. This in turn requires proper and timely diag-
nosis and early establishment of prognosis [7].
This underscores the need for an appropriate and
as-early-as-possible prognostic tool for the selection of
infants who are most likely to suffer moderate to severe
disability and would thus benefit from future personal-
ized neuroprotective protocols.
Proton magnetic resonance spectroscopy (H-MRS) is
one of the tools proposed for such a biomarker [8].
This examination is becoming increasingly widespread
in various medical fields, i.e. tumor diagnosis or neuro-
degenerative diseases. H-MRS usually accompanies
brain magnetic resonance imaging (MRI) scans, and is
capable of registering the spectra of various metabo-
lites present in the examined volume of interest (VOI).
Since water is the molecule most abundantly present
in brain tissue, its acquired spectrum would be several
orders of magnitude higher than those of other metab-
olites; consequently, acquisition of H-MRS requires
suppression of the water signal. This can be achieved
by several acquisition protocols [9]. The analysis of the
acquired spectrum informs the clinician of the meta-
bolic state of the examined tissue, providing valuable
functional information in a non-invasive way. To ac-
quire motionless images during brain MR scans, most
infants require sufficient sedation and intravenous ac-
cess, not all; however, no administration of contrast
material is necessary.
Several studies investigated the prognostic power of
H-MRS in neonatal asphyxia, between 4 h and 46 days
of age [10–19], often covering a wide age range, given
the need for earliest possible prognosis.
Establishing the reproducibility of H-MRS as a prog-
nostic biomarker also poses a problem [20], as previous
studies used a wide range of data-optimizing equipment,
software, or absolute quantification approaches to im-
prove data quality. Taken together, there is no universal
agreement regarding how H-MRS should be applied in
the daily clinical practice.
Aim
The purpose of our study was to determine the prognostic
value of a completely conventional H-MRS sequence (i.e.
without special equipment and post-processing techniques
other than basic vendor-provided analysis), performed
before the 96th hour of life in infants with HIE, analyzing
various metabolite ratios, their age-dependence and asso-
ciation with long-term neurodevelopmental outcome.
Methods
Patient selection
In our retrospective descriptive analysis, we reviewed
all 283 patients with suspected HIE born between
January 2006 and December 2010 and admitted to the
regional cooling center, the Neonatal Intensive Care Unit
(NICU) of the 1st Department of Paediatrics, Semmelweis
University, Budapest, Hungary.
From this patient pool, we only included patients who
(A) fulfilled the diagnostic criteria for moderate to severe
HIE according to the international TOBY trial [21], be-
ing as follows: (i) at least one of the following: continued
need for resuscitation/ventilation at 10 min after birth,
OR Apgar score ≤ 5 at 5 min after birth OR pH < 7.0 or
BE ≤ − 16 mmol/L within 60 min after birth AND (ii)
altered level of consciousness (lethargy, stupor or coma)
AND hypotonia or abnormal reflexes or seizures AND
(iii) abnormal brain background activity registered on
amplitude-integrated electroencephalography (aEEG). Add-
itional inclusion criteria were (B) brain H-MRS scan per-
formed before the 96th postnatal hour AND (C) having a
neurodevelopmental follow-up examination using the
Bayley Scales of Infant Development II between 18 and
26 months of age, as detailed below OR death (< 28 days
of age OR > 28 days associated with HIE).
We excluded all patients who (a) had other underlying
conditions, which could be responsible for encephalopathy
besides asphyxia (i.e. stroke, intracranial hemorrhage, con-
genital malformation or metabolic disease). As only early
onset (< 6 postnatal hours) hypothermia treatment was
thought to be neuroprotective at the time of the study, we
excluded patients who (b) did not receive hypothermia
treatment due to delayed admission. Further exclusion
criteria were: (c) gestational age < 36 weeks and (d) low
quality brain H-MRS.
Altogether, 51 patients met inclusion criteria and were
included in the analysis (Fig. 1).
Clinical care
Whole-body hypothermia treatment was initiated as soon
as possible but within 6 h after delivery, using a water-filled
mattress (Tecotherm©; TecCom, Halle, Germany). The
target rectal temperature was between 33 and 34 °C, main-
tained for 72 h. In the rewarming phase, temperature
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increase velocity was 0.5 °C/h. All infants were ventilated
throughout the cooling and rewarming phase.
Continuous morphine (Morph. hydrochlor. 10 mg/mL;
TEVA Magyarország Zrt., Gödöllő, Hungary) sedation
(10 μg/kg BW/h) was started following the loading dose
(0.1 mg/kg BW) administered when the cooling was
initiated. Phenobarbitone (Gardenal 40 mg; Aventis,
Maisons-Alfort, France, 20 mg/kg BW) was given as
the first line of anticonvulsant therapy if clinical or
electrophysiological seizures were detected. In case of
noncontrolled seizures, the phenobarbitone loading dose
was repeated, or midazolam (Midazolam Torrex 5 mg/ml;
Chiesi Pharmaceuticals GmbH, Vienna, Austria) was given
in single or repeated doses (0.1 mg/kg BW) or in continu-
ous infusion (0.1 mg/kg BW/h). In some cases, newborns
received lidocain, phenytoin, diazepam or chloral hydrate
alternatively, according to the attending clinician’s decision.
The severity of encephalopathy was determined based on
a combination of aEEG background activity at 6 h of age
and Sarnat staging at admission [22]. Infants with abnormal
aEEG pattern by 6 h of age (burst suppression (BS), low
voltage (LV) or flat trace (FT)) OR meeting Sarnat stage 3
criteria were considered having severe encephalopathy. A
normal aEEG pattern (continuous normal voltage (CNV)
or discontinuous normal voltage (DNV)) AND Sarnat stage
1–2 constituted moderate encephalopathy.
H-MRS examination
Proton MR spectroscopy studies were carried out on a 3
Tesla Philips Achieva MRI scanner (Philips Medical Systems,
Fig. 1 Inclusion and exclusion criteria
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Best, The Netherlands), at the MR Research Center of
Semmelweis University, as early as the infant reached
clinical stability and was suitable for transport. All MR
scans were performed between 6th and 96th postnatal
hours (median 25th postnatal hour). The Neonatal Emer-
gency & Transport Services of the Peter Cerny Foundation
provided the neonatal transport and the critical care, in-
cluding hypothermia treatment. For the time of the exam-
ination, the infants were removed from the incubator and
received continuous morphine sedation. In case of intu-
bated infants, skilled personnel provided manual ventilation
with an AMBU bag throughout the MR examination. Con-
tinuous monitoring of transcutaneous oxygen saturation
and capnography was provided for all neonates during the
MR scan, using Medrad Veris MR Monitoring System
(Bayer Healthcare LLC, Whippany, NJ).
Ethical considerations
Patients enrolled did not undergo procedures or inter-
ventions for the purposes of the study. Brain MRI and
H-MRS are part of routine diagnostic imaging in our
unit as a center practice, and are performed on all neo-
nates with suspected moderate-to-severe HIE. Use of
these imaging tools aid in confirming the diagnosis, deter-
mining the timing of and nature of the hypoxic-ischemic
insult (chronic intrauterine or intrapartum), and ruling
out other etiologies. Finally, H-MRS measurements are
not used to redirect clinical care of infants with HIE.
Acquisition protocols
MR spectra were acquired using the PRESS (Point RE-
Solved Spectroscopy) single voxel localization sequence, at
echo-times TE = 35 ms, 144 ms and 288 ms, repetition time
TR = 2000, number of acquisitions NSA = 128. Duration of
scan was approximatively 30 min. The analyzed VOI was a
1 × 1 × 1 cm voxel in the left thalamus of infants, localized
based on gradient echo survey images acquired with TE =
5 ms, TR = 75 ms and 30° flipangle.
Registered metabolites
The most frequently determined and analyzed metabolites
in the H-MRS spectra are N-acetyl-aspartate (NAA), cre-
atine (Cr), choline (Cho), myo-inositol (mIns) and lactate
(Lac).
There are different TE optima for the different metab-
olites, due to their acquisition-dependent signal-to-noise
characteristics, e.g. the Lac’s optimum is at TE = 288 ms,
while for mI either TE = 35 ms or TE = 144 ms suffices.
We recorded peak height, and peak area for all the
above-listed metabolites (Fig. 2).
MR data analysis
We used the vendor-provided data-processing software
on the MR console for analysis without any specific
equipment or tool for data-optimization, in order to ob-
tain results applicable to a general clinical setting. In order
to reproduce basic, non-research center hospital level
circumstances, no data-optimizing equipment or further
post-processing methods were used to ameliorate the reg-
istered spectra.
Since we did not use absolute quantification protocols
due to their high technical requirements, statistical ana-
lysis was carried out on all possible ratios of metabolite
spectral peak heights and peak areas-under-curve, re-
corded at same TE. This resulted in the determination of
overall 36 metabolite ratios (Table 1).
To improve the accuracy of our analyses, we excluded
metabolite ratios derived from metabolite spectra with
signal-to-noise ratio (SNR) below 1, i.e. where noise in-
tensity exceeded signal intensity [23, 24].
Follow-up
Neurodevelopmental follow-up was measured by Bayley
Scales of Infant Development II tool-kit, performed be-
tween 18 and 26 months of age by trained personnel,
blinded to the H-MRS results. We defined poor outcome
as either death (< 28 days of age OR > 28 days associated
with HIE) OR moderately/severely delayed development
(Mental Developmental Index (MDI) or Psychomotor
Developmental Index (PDI) < 70). All other outcomes
were considered as good outcome.
Statistical analysis
Categorical variables are reported as absolute numbers
and percentages while continuous variables as mean ±
standard deviation or median [25th to 75th interquartile
range] depending on the distribution of the parameters.
Shapiro-Wilk test was used to assess normality. Categor-
ical variables were compared with the Fisher’s exact test,
while continuous variables were compared with the
Student t-test or Mann-Whitney U-test for parametric
and non-parametric comparisons, respectively.
To select the best metabolite ratios for prognostica-
tion, a three-step statistical procedure was implemented.
First, we tested the association between the metabolite
ratios and outcome. To adjust for multiple testing, we
used Bonferroni-correction, that is to say, due to 36
examined metabolite ratios, we considered statistical re-
sults significant at p < 0.0014 (0.05/36 = 0.0014).
Second, we considered the fact that in the early hours
after hypoxic insult, the brain metabolic activity shows
extreme variations in time-dependent fashion [25, 26].
Therefore, metabolite ratios measured by H-MRS may
also vary significantly depending on timing of data acqui-
sition. Considering that these metabolic changes are still
not fully understood and described, we aimed to select
metabolite ratios with low or no variability during the first
96 postnatal hours, in order to ensure generalizability of
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our results for all infants within this period, irrespective
of timing of the MR examination. We tested postnatal
age-dependence of metabolite ratios using Spearman
rank-correlation analysis.
Third, we evaluated the prognostic performance of
metabolite ratios using Receiver Operating Characteris-
tics (ROC) curve analysis to establish the potential
cut-off-value (corresponding to the highest likelihood ra-
tio of ROC curves), as well as to determine the sensitiv-
ity, specificity, positive and negative predictive values of
the proposed markers. Moreover, we compared the me-
tabolite ratios as diagnostic tests using the area under
the ROC curve (AUC) using the method described by
Hanley and McNeil [27].
Demographic, clinical and spectral data were analyzed
and plotted using the GraphPad Prism software version
6.0 (GraphPad Software Inc., San Diego, California, USA).
Results
Fifty-one neonates with moderate-to-severe HIE met
the inclusion criteria, and were enrolled in our study.
Hypothermia treatment was initiated before the 6th
postnatal hour for all 51 neonates, with median [IQR] 2
[1.4; 3.1] hours. Forty-five out of the 51 patients had
the H–MRS examination performed while receiving
whole-body hypothermia. The remaining 6 patients had
the examination done before the initiation or after the
completion of hypothermia treatment. Nevertheless, all
scans were performed within 96 h of age.
Clinical characteristics and MRI findings of these patients
are shown in Tables 2 and 3, accordingly, categorized by
long-term outcome. Of the 51 patients, 16 infants were
considered to have poor outcome, including the 9 patients
that died in the perinatal period (i.e. first 28 days), and the
7 patients who had moderately/severely delayed develop-
ment (Mental Developmental Index (MDI) or Psychomotor
Developmental Index (PDI) < 70). Of these 7 patients, 4 in-
fants were diagnosed with cerebral palsy (2 associated with
mental retardation and one with epilepsy), 2 had mental re-
tardation and one patient suffered from neuronal hearing
loss and epilepsy. None of our patients died between 28 days
and the follow-up examination. Good and poor outcome
Fig. 2 Spectrum acquired by H-MRS at echo time (TE) = 35 ms. The registered metabolites are from left to right: Cr2: secondary creatine peak, Glx:
glutamine/glutamate (multiple peaks, here, double peaks), mIns: myo-inositol (double peaks), Cho: choline, Cr: primary creatine peak, NAA: N-
acetyl-aspartate, Lac: lactate, lip: lipid (double peaks). In HIE, metabolites considered to have clinical significance are mIns, Cho, Cr, NAA and Lac.?
represent low (< 1) signal-to-noise ratio (SNR). NB: at TE = 35 ms, the Lac peak is difficult to differentiate from the overlapping lip peaks
Table 1 List of ratios of peak heights and peak areas of the analyzed metabolites: (NAA: N-acetyl-aspartate, Cho: choline, Cr: creatine,
mIns: myo-inositol and Lac: lactate), determined at echo-times TE = 35 ms, 144 ms and 288 ms
TE = 35 ms TE = 144 ms TE = 288 ms
• NAA/Cho height and area
• NAA/Cr height and area
• Cho/Cr height and area
• mIns/NAA height and area
• mIns/Cho height and area
• mIns/Cr height and area
• NAA/Cho height and area
• NAA/Cr height and area
• Cho/Cr height and area
• mIns/NAA height and area
• mIns/Cho height and area
• mIns/Cr height and area
• NAA/Cho height and area
• NAA/Cr height and area
• Cho/Cr height and area
• Lac/NAA height and area
• Lac/Cho height and area
• Lac/Cr height and area
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groups only differed significantly in their 5′ and 10′ Apgar
scores, as well as occurrence of stage 3 HIE seen on MR
images.
Of the 36 metabolite ratios evaluated in the first 96
postnatal hours for prognostication of good or poor neu-
rodevelopmental outcome, 3 metabolite ratios differed sig-
nificantly between the good and poor outcome groups,
rendering them candidates for further analysis (Table 4):
mIns/NAA height (TE = 35 ms), NAA/Cr height (TE =
144 ms) and mIns/Cr height (TE = 35 ms).
Next, we tested the age-dependence of these 3 metab-
olite ratios during the first 96 postnatal hours among all
51 patients, as it has been described that the brain meta-
bolic activity shows extreme time dependent variations






Male sex 19 (51%) 12 (75%) 0.1365
Gestational age (weeks) 39 [38; 40] 38 [37; 40] 0.0536
Birth weight (g) 3261 ± 577 3128 ± 537 0.4379
Apgar 1′ 2 [1; 4] 1 [0; 2] 0.0091
Apgar 5′ 5 [4; 7] 3 [2; 4] 0.0002*
Apgar 10′ 6 [5; 8] 4 [2; 4] 0.0005*
Lowest pH < 1 h of age 7.21 [6.98; 7.28] 7.10 [7.00; 7.20] 0.1643
Highest BD < 1 h of age 14.1 ± 5.9 17.1 ± 4.6 0.0860
Onset of hypothermia (h) 1.8 [1.4; 3.1] 2.1 [1.4; 3.3] 0.6309
Severity of encephalopathy (severe)# 31 (89%) 15 (94%) > 0.9999
Clinical or aEEG seizures (< 24 h) 28 (80%) 14 (88%) 0.7012
Abnormal aEEG pattern (BS, LV, FT) 31 (88%) 12 (75%) 0.2396
aEEG normalization (CNV, DNV) < 72 h 22 (63%) 5 (31%) 0.0681
aEEG normalization time (h) 30 [12; 47] 60 [42; 68] 0.1381
Age at MR scan (h) 25 [14; 49] 30 [16; 54] 0.6625
Abnormalities on MR Imaging (T1/T2 weighted imaging or DWI) 13 (37%) 11 (69%) 0.0681
Death 0 9 (56%) NA†
Data shown as median [IQR], mean ± SD or percentage. Good outcome is defined as both MDI (Mental Developmental Index) and PDI (Psychomotor
Developmental Index) ≥ 70 achieved on Bayley II test, poor outcome is defined as either MDI or PDI < 70 OR death (< 28 days of age OR > 28 days of age
associated with HIE)
BD base deficit, aEEG amplitude-integrated electroencephalography, CNV continuous normal voltage, DNV discontinuous normal voltage, BS burst suppression, LV
low voltage, FT flat trace, DWI diffusion weighted imaging
* represents significant results surviving Bonferroni-correction (p < 0.0014)
# moderate encephalopathy: 6 h normal aEEG pattern (CNV, DNV) AND Sarnat stage 1–2, severe encephalopathy: 6 h abnormal aEEG pattern (BS, LV, FT) OR
Sarnat stage 3 [21]
NA† (not applicable) represents statistical significance not applicable as death was included in the definition of the poor outcome group
Table 3 Location and severity of observed MR Imaging abnormalities in newborns with good versus poor outcome
MRI abnormality and good outcome
(n = 13)




Basal ganglia and thalami 6 (46%) 8 (72%) 0.2397
Internal capsule 5 (38%) 6 (54%) 0.6824
White matter 5 (38%) 0 (0%) 0.0411
Cortex 1 (8%) 1 (9%) > 0.9999
Severity of injury (MRI score)
HIE score 1 3 (23%) 2 (18%) > 0.9999
HIE score 2 6 (46%) 3 (27%) 0.4225
HIE score 3 0 (0%) 8 (72%) 0.0002*
Abnormalities are described as signal intensity abnormality on T1/T2 weighted images, or diffusion abnormality. Severity of injury is described as MR imaging
score of HIE [35], assigned by our neuroradiologist blinded to the newborns’ clinical condition
* represents significant results surviving Bonferroni-correction (p < 0.0014)
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in the early hours after hypoxic insult. We aimed to
search for a uniformly detectable metabolite ratio that
would be suitable for prognostication any time during
the first 4 postnatal days. Assessment of age-dependence
did not show significant correlation between either of
the 3 metabolite ratios and age at the H-MRS examin-
ation. All 3 metabolite ratios showed weak correlation
with the timing of the examination, hence might be
considered relatively stable during the first 96 postnatal
hours (Fig. 3).
Finally, comparing the prognostic performance of these
3 relatively age-independent metabolite ratios, mIns/NAA
height at TE = 35 ms had a better discriminative power
than NAA/Cr height at TE = 144 ms and mIns/Cr height
at TE = 35 ms to identify patients with good versus poor
outcome (cut-off-values 0.6798, 0.6274 and 0.7798, re-
spectively, AUC: 0.9084, 0.8396 and 0.8462, respectively,
difference between ROC curves p < 0.00001). Thus, out of
the 36 evaluated metabolite ratios within the first 96 h of
age, mIns/NAA height at TE = 35 ms seems to give the
best prediction of outcome, with 84.6% sensitivity and
95.2% specificity, irrespective of the timing of the MR
examination (Fig. 4 and Table 5).
Discussion
To the best of our knowledge, this preliminary study
with a relatively small sample size is the first one that inves-
tigated the prognostic accuracy of conventional H-MRS
examination performed during the first 4 postnatal days in
a group of infants with moderate to severe HIE in the era
of hypothermia treatment. We found that myo-inositol/
N-acetyl-aspartate height ratio (TE = 35 ms) was the best
predictor of neurodevelopmental outcome at 2 years of age.
This metabolite ratio proved to have low correlation with
age at MR scan during the first 4 postnatal days and
showed a specificity of 95.2% and a sensitivity of 84.6% for
discriminating between good and poor outcome.
Previously, several studies investigated the prognostic
power of H-MRS in asphyxiated neonates using various
methods, protocols and equipment [10–19]. Neverthe-
less, it is problematic to draw an overarching conclusion
applicable for the general clinical practice, due to the
difference of the methods, findings and conclusions. In-
deed, a wide range of H-MRS derived metabolites were
suggested as potential biomarkers, e.g. some studies con-
cluded that absolute Lac levels and/or Lac-containing
metabolite ratios (Lac/NAA, Lac/Cho, Lac/Cr) were the
most accurate in prediction of outcome [11–14, 16–19],
while others showed that NAA/Cr, NAA/Cho, absolute
NAA and/or Cho levels had promising prognostic pow-
ers [10, 11, 15, 17, 18], but only few studies investigated
glutamate (Glx) or glutamate-containing metabolite ra-
tios (Glx/Cr) [16], and/or mIns [17].
Interpretation and generalizability of these results are
hindered by the fact that there was a marked variability
regarding the methods used, some studies applied various
data-optimizing software [15, 18] methods for absolute
metabolite quantification [14, 15], or special head-coils
[14, 17] in order to ameliorate the information acquired
from the metabolite spectra. These methods may indeed
improve data quality; however, they are not generally ap-
plicable in standard clinical settings [20].
Table 4 Metabolite ratios differing significantly between the outcome groups (p < 0.0014)
Assessed metabolite ratio value of metabolite ratio (median [IQR]) p value
good outcome (n = 35) poor outcome (n = 16)
mIns/NAA height (TE = 35 ms) 0.534 [0.440; 0.601] 0.780 [0.694; 0.894] < 0.0001
NAA/Cr height (TE = 144 ms) 0.990 [0.897; 1.096] 0.808 [0.690; 0.863] < 0.0001
mIns/Cr height (TE = 35 ms) 0.471 [0.387; 0.530] 0.640 [0.528; 0.724] 0.0005
For all other metabolite ratios, see Additional file 1
Fig. 3 Age-correlation diagrams of the 3 metabolite ratios showing strong association with outcome. Measurements from good outcome group
are marked by empty bullet (○), measurements from poor outcome group are marked by circle bullet (●)
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Therefore, our intent was to prove the clinical utility
of conventional H-MRS sequence with vendor-provided
analysis tools in the diagnostic workup of neonatal as-
phyxial encephalopathy.
Despite their limitations, existing evidence largely
supports the use of peak areas as prognostic markers in
patients with neonatal encephalopathy. A meta-analysis
concluded that deep gray matter Lac/NAA peak area
ratio is the most accurate predictor of adverse outcome
[28]. Based on Bottomley’s comprehensive review of MR
spectroscopy [29] however, without post-processing tech-
niques, the use of peak height and peak area has certain
challenges. While peak height provides an acceptable meas-
ure for non-overlapping peaks, it is affected by patient
motion and inhomogeneous widening of spectrum widths.
Peak areas are relatively immune to motion artefacts and
spectrum widening. However, since most of the integrated
area of a peak resides near its base, noise and overlapping
of other peaks can significantly affect the measurements.
Taking these factors into consideration, we assessed the
prognostic value of both peak heights and peak areas.
Based on our findings, it seems that without the use of
post-processing, peak height may have an appropriate
predictive value and might be useful in the common
clinical setting without the use of specialized imaging
and post-processing techniques.
We set out to find markers that have similar or pos-
sibly even higher value for prognostication than markers
published earlier.
To this end, we targeted our investigation on H-MRS
scans performed the earliest possible, within 96 postnatal
hours, presuming that the earlier the accurate prognostic
information, the higher its clinical importance. The major-
ity of the above-listed studies investigated H-MRS scans
that were performed significantly later and in a wider range
of infant age (3 to 45 days of age) [10, 11, 15–19], with only
three papers focusing on early infant ages similar to our
study [12–14], all three analyzing considerably small patient
cohorts. One of them investigated infants during their first
day of life (31 neonates of 4–18 postnatal hours); however,
considering the unstable clinical status of many severely as-
phyxiated infants, this may be unfeasible in the clinical
practice [12]. The second paper (11 neonates of 12–48
postnatal hours) concluded that only combined H-MRS
and diffusion-weighted imaging is capable of accurate pre-
diction of outcome [13], while the third one (17 neonates
of 48–96 postnatal hours) used absolute quantification and
a custom-made head-coil to optimize data acquisition [14].
Nevertheless, none of these early-acquisition studies exam-
ined neonates while undergoing therapeutic hypothermia.
In addition, although a recent study examined 88 in-
fants with perinatal asphyxia who underwent therapeutic
hypothermia, MR scans and H-MRS were acquired only
within the first 7 postnatal days [30].
In the era of therapeutic hypothermia, the effect of
cooling on brain metabolites is an important issue. Exist-
ing evidence suggests that hypothermia increases the
clearance of lactate upon cerebral reperfusion [31] and
increases overall lactate and myo-inositol levels in the
cortex, while increasing the level of taurine and decreasing
the level of choline in the thalamus [32]. Even though fur-
ther studies are needed to outline the hypothermia-induced
changes in metabolites detected by H-MRS, these find-
ings suggest that thalamic myo-inositol/N-acetyl-aspar-
tate values are not affected by cooling.
As an essential step in our analysis, we searched for
metabolite ratios independent from postnatal age at the
MR examination. It is well-known that in the early hours
after hypoxic insult, the brain has an extremely dynamic
metabolic profile [25, 26], so theoretically, metabolite
ratios measured by H-MRS may vary significantly depend-
ing on the timing of the MR examination. In addition, the
timing of the MR scan is influenced by the clinical stability
of newborns. Based on these considerations, the acquisition
of a single cut-off value for the proposed biomarker suitable
Fig. 4 Receiver Operating Characteristics (ROC) curves of metabolite
ratios showing weak correlation with age at scan. The area under
the ROC curve was 0.9084 for mIns/NAA (TE = 35 ms), 0.8396 for
NAA/Cr (TE = 144 ms) and 0.8462 for mIns/Cr (TE = 35 ms)
heights (p < 0.00001)
Table 5 Results of Receiver Operating Characteristics (ROC) analysis
Assessed metabolite ratio Cut-off-value Area under curve (AUC) Sensitivity Specificity Positive predictive value Negative predictive value
mIns/NAA height (TE = 35 ms) 0.6798 0.9084 84.62% 95.24% 91.67% 90.91%
NAA/Cr height (TE = 144 ms) 0.7798 0.8396 70.59% 85.29% 75,00% 75,61%
mIns/Cr height (TE = 35 ms) 0.6274 0.8462 61.54% 95.24% 88.89% 80.00%
Difference between ROC curves was significantly different (p < 0.00001)
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for differentiation between outcomes may be extremely
complex, given that the time-dependent metabolite changes
are still not fully understood and described. Subsequently,
the prognostic markers that vary depending on patient
age may show false negative or false positive results, if
performed too early or too late in the examined time
period, so would require a dynamic range of cut-off-values
(cut-off-curve) which calls for considerably larger popula-
tion and/or repeated measures. Conclusively, until the
precise kinetics of brain metabolites are described, the
cut-off-value of the proposed prognostic marker should
ideally not change with time but should only be deter-
mined by severity of encephalopathy and potential out-
come. None of the existing studies contemplated the
possible postnatal age dependence of the observed metab-
olites or metabolite ratios. Therefore, we aimed to investi-
gate the stability of metabolite ratios, and found that none
of the 3 metabolite ratios associated with outcome showed
correlation with timing of the examination in the investi-
gated time window, hence could be potentially independ-
ent of postnatal age. We consider the contemplation of
the time-dependence of brain metabolites as one of the
strengths of our analysis, even though further dependence
analyses in repeated measures and larger population are
needed to confirm our findings.
Existing evidence suggests that the role of both myo-
inositol and N-acetyl-aspartate is complex. Myo-inositol
is a pentose sugar, precursor for inositol-derived lipid
synthesis and part of the intracellular second-messenger
system [33]. To date, studies suggest that myo-inositol
could be the breakdown product of abnormal cerebral
inositol-polyphosphate metabolism and the cell mem-
brane component myelin [34], implementing that in-
creased myo-inositol levels signal cell death.
N-acetyl-aspartate is the second most abundant amino
acid in the brain, functioning as an osmolite with multiple
functions, e.g. molecular water pump for neurons to help
osmotic regulation, as well as source, storage and trans-
port of acetyl-group, aspartate and amino-nitrogen, for
protein and lipid synthesis [33]. Studies suggest that NAA
levels decrease after neuronal injury or dysfunction, even
in the absence of cell death [34].
Conclusively, neuronal injury induced by hypoxia-is-
chemia is considered to raise myo-inositol levels and de-
crease N-acetyl-aspartate levels, thus increasing myo-
inositol/N-acetyl-aspartate ratio and providing scientific
background for our findings.
It is surprising that none of the lactate-containing me-
tabolite ratios met the strict significance requirements of
Bonferroni-correction. One of the reasons for this find-
ing might be the low quality of lactate spectral data. In
our measurements, signal-to-noise ratio of lactate peaks
were extremely low, with a median [IQR] signal-to-noise
ratio of 1.0 [0.7; 1.6] without selection, and 1.6 [1.1; 2.5]
after selection based on SNR = 1 criterion. However, low
spectral data quality only affected peaks of lactate, since
all other metabolites showed significantly more favorable
signal-noise characteristics, with a median [IQR] signal-
to-noise ratio of 10.8 [8.0; 12.8] for N-acetyl-aspartate,
11.9 [8.8; 14.5] for choline, 11.4 [7.3; 13.9] for creatine
and 5.7 [4.8; 7.5] for myo-inositol, reflecting significantly
better data quality. Based on these findings, spectral peak
of lactate cannot be accurately assessed and interpreted in
the general clinical setting and in the absence of post-pro-
cessing techniques, despite its widespread use in previous
studies.
In our study, the volume of interest was a 1 × 1 × 1 cm
voxel in the left thalamus. In this cohort, only one patient
presented with watershed injury in the left parieto-occipital
region, and one patient with widespread cortical lesion.
Due to the low prevalence of watershed lesions, we were
unable to assess the prognostic value of H-MRS in this type
of neuronal injury.
Our study also has a number of limitations. Even though
we outlined our methodology to eliminate all possible
errors, there are certain points that still might have given
way to inaccuracy in our conclusions. First, our study is
retrospective in nature, therefore we could not control for
factors possibly affecting the findings such as the imaging
process and the clinical parameters. This may be consid-
ered a limitation compared to a prospective clinical study,
where imaging and clinical parameters would have been
fine-tuned for the purpose of the study. On the other
hand, this could be viewed as a strength from a clinical
standpoint, since we had to rely on data that could have
been obtained in any MR facility imaging asphyxiated neo-
nates. Therefore, our findings might have more relevance
in the general clinical practice. The small sample size of
our population is another limitation decreasing the accur-
acy and reliability of the statistical analysis. The difference
between the sizes of the outcome groups (35 good versus
16 poor) might also be considered as a limitation, as our
analysis might have been underpowered. Moreover, some
may criticize our approach, and may state that all neo-
nates should be examined at the exact same age, which
would enable prognostic results to be as accurate as pos-
sible. However, considering that infants cannot be assessed
before reaching certain clinical stability, this would not be
a realistic expectation in the clinical practice.
Obviously, our results must be verified in prospective
trials on larger populations and on different MR scanners
to corroborate the prognostic power of the proposed
H-MRS metabolite ratios.
Conclusions
In summary, we propose that H-MRS performed before
96 h of age is a potentially promising tool for early pre-
diction of outcome in asphyxiated neonates. The use of
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H-MRS may add valuable information for the clinicians to
assess the severity of the hypoxic insult and potentially
utilize additional neuroprotective therapies. Furthermore,
our results suggest that even conventional H-MRS might
have a high enough prognostic accuracy to be used in rou-
tine clinical practice.
Additional file
Additional file 1: Results of Mann-Whitney test for all metabolite ratios.
Data are shown as median [IQR], results were considered significant
at p < 0.0014 (after Bonferroni correction). (XLSX 10 kb)
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